ABA-101 for Multiple Sclerosis
Trial Summary
What is the purpose of this trial?
This study will test the safety and effects of ABA-101 when given as a single dose to participants with progressive multiple sclerosis. It is the first study of this treatment in humans. After safety is demonstrated with a low dose of ABA-101, a higher dose will be evaluated.
Will I have to stop taking my current medications?
The trial requires that participants are not currently on disease-modifying therapies (DMTs), so you would need to stop taking those medications to join.
Eligibility Criteria
This trial is for adults over 18 with progressive multiple sclerosis, confirmed by the McDonald criteria. Participants must show signs of brain inflammation on MRI, have worsening disability not linked to MS relapses, match a specific genetic marker (HLA), and meet certain physical function tests.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single ascending dose of ABA-101, starting with a low dose followed by a high dose after safety is demonstrated
Follow-up
Participants are monitored for safety and effectiveness after treatment, with adverse events tracked through Day 29
Treatment Details
Interventions
- ABA-101
ABA-101 is already approved in United States for the following indications:
- Progressive Multiple Sclerosis (under investigation, not approved)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Abata Therapeutics
Lead Sponsor